Patents by Inventor Christopher E. Newall

Christopher E. Newall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 4621081
    Abstract: Cephalosporin antibiotics of general formula: ##STR1## (wherein R.sup.a and R.sup.b, which may be the same or different, each represent a C.sub.1-4 alkyl group or R.sup.a and R.sup.b together with the carbon atom to which they are attached form a C.sub.3-7 cycloalkylidene group, and Y.sup..sym. represents a C-linked 5- or 6-membered heterocyclic ring containing at least one C.sub.1-4 alkyl-substituted quaternary nitrogen atom, which ring may also contain one or more sulphur atoms) exhibit broad spectrum antibiotic activity, the activity being unusually high against gram-negative organisms such as strains of Pseudomonas organisms.A particular antibiotic compound of formula (I) possessing excellent antibacterial activity against strains of Pseudomonas organisms, as well as other valuable therapeutic properties, is (6R,7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-(1-carboxycyclobut-1-oxyimino)ace tamido]-3-[(1-methylpyridinium-4-yl)-thiomethyl]ceph-3-em-4-carboxylate.
    Type: Grant
    Filed: September 27, 1982
    Date of Patent: November 4, 1986
    Assignee: Glaxo Group Limited
    Inventors: Cynthia H. O'Callaghan, Barry E. Ayres, David G. H. Livermore, Christopher E. Newall, Niall G. Weir
  • Patent number: 4600772
    Abstract: Cephalosporin antibiotics of the general formula ##STR1## (wherein R.sup.a and R.sup.b, which may be the same or different, each represent a C.sub.1-4 alkyl group or R.sup.a and R.sup.b together with the carbon atom to which they are attached form a C.sub.3-7 cycloalkylidene group; and R.sup.4 represents hydrogen or a 3- or 4-carbamoyl group) exhibit broad spectrum antibiotic activity, the activity being unusually high against gram-negative organisms such as strains of Pseudomonas organisms. A particular antibiotic compound of formula (I) possessing excellent antibacterial activity against strains of Pseudomonas organisms, as well as other valuable therapeutic properties, is (6R,7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-(2-carboxyprop-2-oxyimino) acetamido]-3-(1-pyridiniummethyl)-ceph-3-em-4 carboxylate. The invention also includes the non-toxic salts and non-toxic metabolically labile esters of compounds of formula (I).
    Type: Grant
    Filed: September 13, 1982
    Date of Patent: July 15, 1986
    Assignee: Glaxo Group Limited
    Inventors: Cynthia H. O'Callaghan, David G. H. Livermore, Christopher E. Newall
  • Patent number: 4504477
    Abstract: Cephalosporin antibiotics of general formula ##STR1## (wherein Y.sup..sym. represents a C-attached 1-C.sub.1-4 alkylpyridinium group) exhibit broad spectrum antibiotic activity with unusually high activity against strains of Pseudomonas organisms as well as high activity against various members of the Enterobacteriaceae. The invention also includes the non-toxic salts, non-toxic metabolically labile esters and 1-oxides of compounds of formula (I). Also described are compositions containing the antibiotics of the invention and processes for the preparation of the antibiotics.
    Type: Grant
    Filed: July 21, 1981
    Date of Patent: March 12, 1985
    Assignee: Glaxo Group Limited
    Inventors: Cynthia H. O'Callaghan, Barry E. Ayres, David G. H. Livermore, Christopher E. Newall, Niall G. Weir
  • Patent number: 4464368
    Abstract: Cephalosporin antibiotics of general formula ##STR1## (wherein R.sup.a and R.sup.b, which may be the same or different, each represent a C.sub.1-4 alkyl group, or together with the carbon atom to which they are attached form a C.sub.3-7 cycloalkylidene group and R.sup.1 represents a C.sub.1-4 alkyl group) exhibit broad spectrum antibiotic activity, the activity being unusually high against gram-negative organisms such as strains of Pseudomonas organisms.Particularly effective compounds of formula (I) are (6R,7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-(2-carboxyprop-2-oxyimino)acetami do]-3-(2-methylpyrazolium-1-ylmethyl)ceph-3-em-4-carboxylate and (6R,7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-[(1-carboxycyclobut-1-oxyimino)ac etamido]-3-(2-methylpyrazolium-1-ylmethyl)]ceph-3-em-4-carboxylate.
    Type: Grant
    Filed: July 23, 1981
    Date of Patent: August 7, 1984
    Assignee: Glaxo Group Limited
    Inventors: Cynthia H. O'Callaghan, Barry E. Ayres, Christopher E. Newall, David G. H. Livermore, Derek R. Sutherland
  • Patent number: 4427675
    Abstract: Cephalosporin antibiotics of general formula ##STR1## (wherein R.sup.a and R.sup.b, which may be the same or different, each represent a C.sub.1-4 alkyl group, or together with the carbon atom to which they are attached form a C.sub.3-7 cycloalkylidene group). These compounds exhibit broad spectrum antibiotic activity, the activity being unusually high against gram-negative organisms such as strains of Pseudomonas organisms.Particularly effective compounds of formula (I) are (6R,7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-(2-carboxyprop-2-oxyimino)acetami o]-3-(pyridazinium-1-ylmethyl)ceph-3-em-4-carboxylate and (6R,7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-(t-carboxycyclobut-1-oxyimino)ace tamido]-3-(pyridazinium-1-ylmethyl)ceph-3-em-4-carboxylate. The invention also includes the non-toxic salts and non-toxic metabolically labile esters of compounds of formula (I), compositions containing the antibiotic compounds of the invention and a method of combatting bacterial infection utilizing the antibiotics.
    Type: Grant
    Filed: September 29, 1981
    Date of Patent: January 24, 1984
    Assignee: Glaxo Group Limited
    Inventors: Barry E. Ayres, Cynthia H. O'Callaghan, David G. H. Livermore, Christopher E. Newall
  • Patent number: 4290949
    Abstract: 2-Vinylclavem compounds are disclosed which have been found of value in the synthesis of thio-derivatives of clavulanic acid which possess antibiotic and .beta.-lactamase inhibitory activity. Methods for preparing the vinylclavem compounds are disclosed and processes for preparing the thio-derivatives are given.
    Type: Grant
    Filed: June 24, 1977
    Date of Patent: September 22, 1981
    Assignee: Glaxo Operations UK Limited
    Inventors: Peter C. Cherry, Christopher E. Newall, Nigel S. Watson, Gordon I. Gregory, Peter Ward
  • Patent number: 4258041
    Abstract: Cephalosporin antibiotics of the general formula ##STR1## (wherein R.sup.a and R.sup.b, which may be the same or different, each represent a C.sub.1-4 alkyl group or R.sup.a and R.sup.b together with the carbon atom to which they are attached form a C.sub.3-7 cycloalkylidene group; and R.sup.4 represents hydrogen or a 3- or 4-carbamoyl group) exhibit broad spectrum antibiotic activity, the activity being unusually high against gram-negative organisms such as strains of Pseudomonas organisms. A particular antibiotic compound of formula (I) possessing excellent antibacterial activity against strains of Pseudomonas organisms, as well as other valuable therapeutic properties, is (6R,7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-(2-carboxyprop-2-oxyimono) acetamido]-3-(1-pyridiniummethyl)-ceph-3-em-4 carboxylate. The invention also includes the non-toxic salts and non-toxic metabolically labile esters of compounds of formula (I).
    Type: Grant
    Filed: May 25, 1979
    Date of Patent: March 24, 1981
    Assignee: Glaxo Group Limited
    Inventors: Cynthia H. O'Callaghan, David G. H. Livermore, Christopher E. Newall
  • Patent number: 4228074
    Abstract: .beta.-Lactam compounds of the formula (I) ##STR1## (wherein R represents an esterified carboxyl group, --NR.sup.1 R.sup.2 R.sup.3 represents the residue of a nitrogen base, and R.sup.4 represents a hydrogen atom, a hydroxyl group or acylated or etherified hydroxyl group or the residue of a sulphur nucleophile) are disclosed, together with processes for their preparation. The compounds are valuable intermediates for the preparation or purification of further .beta.-lactam compounds having .beta.-lactamase inhibitory activity.
    Type: Grant
    Filed: September 8, 1977
    Date of Patent: October 14, 1980
    Assignee: Glaxo Laboratories Limited
    Inventors: Peter C. Cherry, Christopher E. Newall, Nigel S. Watson